Edition:
India

Alimera Sciences Inc (ALIM.OQ)

ALIM.OQ on NASDAQ Stock Exchange Global Market

1.30USD
15 Dec 2017
Change (% chg)

$0.00 (+0.00%)
Prev Close
$1.30
Open
$1.30
Day's High
$1.32
Day's Low
$1.28
Volume
9,980
Avg. Vol
28,062
52-wk High
$1.71
52-wk Low
$1.06

Chart for

About

Alimera Sciences, Inc. (Alimera) is a pharmaceutical company. The Company is engaged in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company operates through two segments: U.S. and International. The Company focuses on diseases affecting the back of the eye or retina. The... (more)

Overall

Beta: 2.27
Market Cap(Mil.): $95.64
Shares Outstanding(Mil.): 69.05
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.14 16.44
EPS (TTM): -- -- --
ROI: -- 14.86 10.62
ROE: -- 16.28 14.20

BRIEF-Alimera Sciences Inc reports qtrly loss per share ‍$0.08​

* Alimera Sciences Inc reports third quarter 2017 financial results

02 Nov 2017

BRIEF-Alimera Sciences files for mixed shelf of up to $100 mln‍​

* Alimera Sciences Inc files for mixed shelf of up to $100 million – SEC filing ‍​ Source text - (http://bit.ly/2yCWftF) Further company coverage:

23 Oct 2017

BRIEF-Alimera Sciences ‍announces Iluvien now available in Ireland​

* Alimera Sciences Inc - ‍Announces Iluvien now available in Ireland​ Source text for Eikon: Further company coverage:

13 Sep 2017

BRIEF-Alimera Sciences signs agreement for distribution of Iluvien in France

* Alimera Sciences signs agreement for exclusive distributor of Iluvien in France

30 Aug 2017

BRIEF-Alimera Sciences Q2 ‍net loss per share $0.04​

* Alimera Sciences reports second quarter 2017 financial results

03 Aug 2017

BRIEF-Alimera Sciences announces real-world audit data supporting positive benefits of iluvien treatment

* Alimera Sciences announces real-world audit data supporting the positive benefits of iluvien treatment

26 Jul 2017

BRIEF-Alimera Sciences announces italian patients now being treated with Iluvien

* Alimera Sciences announces italian patients now being treated with Iluvien® Source text for Eikon: Further company coverage:

12 Jul 2017

Competitors

Earnings vs. Estimates